Another interesting setting is evaluating the efficacy of 177Lu-PSMA-I&T as a first-line treatment for oligometastatic prostate cancer relapse after prior surgery or external radical radiotherapy for local disease (Table 1, NCT04443062). Here, FOLH1 is linked to prostate cancer.